Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Cortes, Claudia P ^a   Sterling, Timothy R ^b,b   McGowan, Catherine C ^b   Shepherd, Bryan E ^b   Duda, Stephany N ^b   Jenkins, Cathy A ^b,b   Gonzalez, Elsa ^c,c   Carriquiry, Gabriela ^c   Schechter, Mauro ^d   Padgett, Denis ^e   Cesar, Carina ^f,f   Madero, Juan Sierra ^g,g   Pape, Jean W ^h   Masys, Daniel R ^b   Wolff, Marcello ^a   Arancibia, José Miguel ^a   Saavedra, Felipe ^a   Salinas, Carolina ^a   Mayer, Erick ^c   Condorhuaman, Patricia ^c   Gotuzzo, Eduardo ^c   Tuboi, Suely H ^d   Fink, Valeria ^f   Sued, Omar ^f   Cahn, Pedro ^f   Crabtree, Brenda ^g   Bacon, Melanie ⁱ   Williams, Carolyn ⁱ   more..

^a UNIVERSITY OF CHILE   (Chile)

^b VANDERBILT UNIVERSITY   (United States)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e Inst Hondureno de Seguridad Social   (Honduras)

^f FUNDACIÓN HUÉSPED   (Argentina)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; TREATMENT DURATION; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS;

EID: 84884200658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074057     Document Type: Article

References (27)

1. World Health Organization (2012) Global tuberculosis report. WHO/HTM/TB/(2012) 6.
2. Leonard MK, Larsen N, Drechsler H, Blumberg H, Lennox JL, et al. (2002) Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991--2000. Clin Infect Dis 34: 1002-1007. doi:10.1086/339448. PubMed: 11880967.
3. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75-83. doi:10.1097/00002030-200201040-00010. PubMed: 11741165.
4. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, et al. (2003) Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 17: 2615-2622. doi:10.1097/00002030-200312050-00008. PubMed: 14685055.
5. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 1471-1481. doi:10.1056/NEJMoa1013911. PubMed: 22010913.
6. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-1491. doi:10.1056/NEJMoa1013607. PubMed: 22010914.
7. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501. doi:10.1056/NEJMoa1014181. PubMed: 22010915.
8. Koenig SP, Riviere C, Leger P, Joseph P, Severe P, et al. (2009) High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 48: 829-831. doi:10.1086/597098. PubMed: 19207078.
9. Sterling TR, Lau B, Zhang J, et al. (2011) Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. J Infect Dis 204: 893-901. doi:10.1093/infdis/jir421. PubMed: 21849286.
10. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. (2007) Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21: 713-719. doi:10.1097/QAD.0b013e328013f632. PubMed: 17413692.
11. Moore DM, Yiannoutsos CT, Musick BS, Tappero J, Degerman R, et al. (2011) Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 58: 289-296. doi:10.1097/QAI.0b013e3182303716. PubMed: 21857358.
12. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662. doi:10.1164/rccm.167.4.603. PubMed: 12588714.
13. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC, (2006) International standards for tuberculosis care. Lancet Infect Dis 6: 710-725. doi:10.1016/S1473-3099(06)70628-4. PubMed: 17067920.
14. World Health Organization (2010) Treatment of tuberculosis: guidelines. 4th.
15. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, et al. (2004) Risk factors for relapse and acquired rifamycin resistance after directly-observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin. Clin Infect Dis 38: 731-736. doi:10.1086/381675. PubMed: 14986259.
16. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, et al. (2007) Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 175: 1199-1206. doi:10.1164/rccm.200509-1529OC. PubMed: 17290042.
17. Khan FA, Minion J, Pai M, Royce S, Burman W, et al. (2010) Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 50: 1288-1299. doi:10.1086/651686. PubMed: 20353364.
18. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, et al. (2010) Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 181: 743-751. doi:10.1164/rccm.200903-0439OC. PubMed: 19965813.
19. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS, (2001) Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 33: 1762-1769. doi:10.1086/323784. PubMed: 11595988.
20. Pulido F, Pena JM, Rubio R, Moreno S, Gonzalez J, et al. (1997) Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 157: 227-232. doi:10.1001/archinte.1997.00440230105014. PubMed: 9009982.
21. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, et al. (2007) Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36: 969-976. doi:10.1093/ije/dym073. PubMed: 17846055.
22. Perriëns JH, Louis St, Mukadi YB, Brown C, Prignot J, et al. (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 332: 779-784. doi:10.1056/NEJM199503233321204. PubMed: 7862181.
23. Lawn SD, Wilkinson RJ, Lipman MC, Wood R, (2008) Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 177: 680-685. doi:10.1164/rccm.200709-1311PP. PubMed: 18202347.
24. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523. doi:10.1016/S1473-3099(08)70184-1. PubMed: 18652998.
25. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR, (2009) Unmasked Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Disease: A Disease Spectrum after Initiation of Antiretroviral Therapy. J Infect Dis 199: 437-444. doi:10.1086/595985. PubMed: 19090776.
26. Ali K, Klotz SA, (2011) The Immune Reconstitution Inflammatory Syndrome with Tuberculosis: A Common Problem in Ethiopian HIV-Infected Patients Beginning Antiretroviral Therapy. J Int Assoc Physicians AIDS Care (Chic).
27. Dibyendu D, Sarkar RN, Phaujdar S, Bhattacharyya K, Pal HK, (2011) Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients. Braz J Infect Dis 15: 553-559. doi:10.1016/S1413-8670(11)70250-1. PubMed: 22218514.